Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteome SciencesCHIX:PRML Cash-to-Debt is 0.05 as of Dec. 2025, which is 62% below its 10-year median of 0.13. The stock has 6 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 92.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Proteome Sciences's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.05.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Proteome Sciencescouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Proteome Sciences's Cash-to-Debt or its related term are showing as below:
CHIX:PRMl'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.13 Max: 0.34
Current: 0.05
During the past 13 years, Proteome Sciences's highest Cash to Debt Ratio was 0.34. The lowest was 0.05. And the median was 0.13.
CHIX:PRMl's Cash-to-Debt is ranked worse than 92.86% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.055
vs CHIX:PRMl: 0.05
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Proteome Sciences Cash-to-Debt Related Terms
Proteome Sciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:PRML vs TMO, DHR, IDXX: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (CHIX:PRML) has a Cash-to-Debt of 0.05 as of Dec. 2025. This is 62% below median its historical median of 0.13. Over the past decade, Proteome Sciences' Cash-to-Debt has ranged from 0.05 to 0.34. According to the industry distribution chart, Proteome Sciences ranks #195 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 92.9%.
Is Proteome Sciences' Cash-to-Debt too high?
Proteome Sciences' current Cash-to-Debt of 0.05 is 62% below median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.34. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.06. Proteome Sciences' value of 0.05 is 95.3% below this industry median. Based on the distribution chart, Proteome Sciences ranks #195 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #195 out of 210 companies for Cash-to-Debt. This places Proteome Sciences in the lower half of its industry. The industry median Cash-to-Debt is 1.06. Proteome Sciences' value of 0.05 is 95.3% below this benchmark. Historically, Proteome Sciences' own Cash-to-Debt has ranged from 0.05 to 0.34 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 1.06, Proteome Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.06, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteome Sciences's current Cash-to-Debt of 0.05 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current Cash-to-Debt is 0.05, which is 62% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading right at its estimated fair value. The current Cash-to-Debt is 0.05, which is 62% below median its 10-year median of 0.13 and 95.3% below the Medical Diagnostics & Research industry median of 1.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Cash-to-Debt is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRML has been successfully added to your 
